CSPC：SYS6051 has received its first clinical trial approval.
In March 2026, SYS6051, developed by CSPC Pharmaceutical Group’s Jushi Biopharmaceutical, received clinical trial approval in China for the indication of advanced solid tumors. The drug has also received clearance from the U.S. FDA to conduct clinical trials.
SYS6051 is an ADC targeting human tissue factor (TF). This candidate drug binds to tissue factor on the surface of tumor cells, enters the cells through internalization, and releases a toxin to kill tumor cells. CSPC Pharmaceutical Group is currently conducting a Phase I clinical study (CTR20261816) in China to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity of SYS6051 in patients with advanced solid tumors.
Buy SYS6051 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
